Retina Forum: Focus on Therapeutics That Extend Treatment Intervals in nAMD and DME

Author(s)/Faculty: Caroline R. Baumal, MD, FASRS; Arshad M. Khanani, MD, MA, FASRS; Michael A. Singer, MD; Christina Y. Weng, MD, MBA
Release Date: 12/16/2022Expiration Date: 12/15/2023
Credit Type: CMENumber of Credits: 1.25
Content Type: VideoProvider:
Pinnacle clinical trials in diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD) have demonstrated significant visual and anatomical improvements through treatment with anti-vascular endothelial growth factor (VEGF) therapies. Corticosteroid therapy is also an effective option for DME but is often not effectively integrated into treatment protocols. Improvements in visual and anatomical outcomes with real-world application of anti-VEGF therapies do not always align with those seen in pinnacle studies due to treatment burden and incomplete responses to therapy. To address these inconsistences in outcomes, treatment protocols using FDA-approved therapies continue to be refined, whereas novel delivery systems, gene therapies, and agents with unique mechanisms of action seek to address treatment burden through extending dosing intervals. In this CME series, experts in the field examine the current need for treatments that reduce the burden of frequent anti-VEGF injections for the management of nAMD and DME, assess approved therapies based upon their efficacy and safety in clinical studies, review the evidence about new and emerging surgical delivery systems that reduce treatment burden, and provide best practices that can reduce the potential for complications when implanting and refilling the Port Delivery System with ranibizumab.